Candela Cives Losada, PhD, is a basic and translational scientist with a strong background in cancer biology and drug resistance. She holds a Bachelor’s degree in Biotechnology and a Master’s degree in Cellular and Molecular Pathophysiology and Pharmacology from the University of Salamanca (Spain), where she completed her end-of-degree research projects on the role of bile acids in pathophysiology within the Experimental Hepatology and Drug Delivery (HEVEPHARM) group.

She continued her postgraduate training within the HEVEPHARM group, earning a PhD with international distinction in Pathophysiology and Pharmacology from the University of Salamanca in 2023, followed by a year of postdoctoral research. Her work focused on elucidating the mechanisms of chemoresistance in liver cancers, particularly hepatoblastoma and cholangiocarcinoma, with the goal of identifying potential biomarkers and therapeutic targets for novel pharmacological strategies.

Her scientific training was further enriched by an international research stay at Johannes Gutenberg University in Mainz (Germany), where she explored chemosensitization strategies based on the inhibition of ABC transporters.
Driven by her deep interest in cancer research, she is currently a postdoctoral fellow involved in the LANCELOT project, led by Prof. Matteo Donadon from the University of Piemonte Orientale (Novara, Italy), in collaboration with the Hepatobiliary Immunopathology Lab headed by Prof. Ana Lleo at IRCCS Humanitas Research Hospital (Milan, Italy). The project aims to characterize the immune landscape of liver metastatic colorectal cancer.